Imunon, Inc. (IMNN): Entry into a Material Definitive Agreement

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously reported, on June 2, 2026, Imunon, Inc. (the “ Company ”) entered into a securities purchase agreement with Streeterville Capital, LLC (the “ Investor ”), providing for the issuance and sale by the Company, and t

Event · Offering · proposed
Instrument
Series B Preferred Stock
Shares
120 shares
Price per share
$10,000 per share

Facts are quoted from the filing text and checked against it.

Original reporting
Published Sep 29, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 12:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$IMNN
Neutral
medium confidence
Mentioned
$IMNN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$IMNNNeutralLow
01

Why it matters

The filing confirms new capital but introduces preferred equity with an 8% return and redemption features, which may affect valuation and liquidity.

02

Market read

A primary 8‑K disclosure for a micro‑cap; modest relevance for traders monitoring financing events.

03

What to watch

Potential covenant restrictions and higher preferred return rates if default events occur.

Relevance 6/10Novelty 6/10Timing: filed Sep 29 2026

Background

Imunon, a micro‑cap listed on the Nasdaq under ticker IMNN, disclosed a financing transaction involving preferred stock and secured notes.

Company-level read

Ticker impact

$IMNNNeutralMedium confidence
Context

Imunon filed an 8‑K reporting a securities purchase agreement issuing Series A preferred shares and secured notes raising $2.5 million and a $7.72 million exchange of notes for Series B preferred shares.

Expected impact

likely slight upward pressure as the market prices in the new financing and note exchange

Evidence & confidence

Primary disclosure of a material agreement; amount is modest for a micro‑cap, so impact is limited but the confirmed funding can support operations.

Market effects

Provides a data point on financing activity in the biotech/health‑tech micro‑cap space.

Limited to U.S. over‑the‑counter micro‑cap investors.

Minimal; does not affect broader market indices.

Counterpoint

The dilution from preferred shares could outweigh the cash benefit, leading to a price decline.

Key entities

  • Imunon, Inc.

    Issuer of the securities purchase agreement.

  • Streeterville Capital, LLC

    Counterparty purchasing the preferred shares and notes.

Related articles

$IMNNMedAI 8/10

Imunon (IMNN) Q3 2026 Earnings Call Transcript

Imunon (IMNN) reported Q3 2026 progress, highlighting Phase III IMNN-001 study for ovarian cancer. The company saw strong enrollment, independent validation, and a partnership with the National Cancer Institute. IMNN-001 aims to address a disease with low survival rates and limited treatment advances. The company expects 50% enrollment by Q1 2028 and completion by Q1 2029, with interim analysis in Q1 2030.

$IMNNLow

Imunon 3Q 2026: EPS ($0.64) — 10-Q Summary

Imunon (IMNN) reported a wider net loss of $3.81M in Q3 2026, though diluted EPS improved to ($0.64) from ($1.16) YoY. Operating expenses decreased 1%, with R&D costs down 6%. The OVATION 3 trial enrollment exceeded expectations, and the company advanced its NCI collaboration and MRD study. Imunon discontinued PLACCINE and IMNN-101 development in Q1 2026.

$IMNNMed

Imunon Reports Q3 2026 Net Loss of $3.8 Million and Advances IMNN-001

Imunon reported a Q3 2026 net loss of $3.8M, or $0.64 per share, compared to $3.4M, or $1.16 per share, a year earlier. Operating expenses were $3.4M. The company updated its Phase 3 ovarian cancer study and other programs, with enrollment expected to complete by Q1 2029. Imunon also transferred ThermoDox rights to VoxelDox, contingent on funding.

$IMNNHighAI 8/10

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollm

$IMNNHighAI 8/10

IMUNON presents translational data from ovarian cancer trial

IMUNON Inc. (IMNN) presented data from its Phase 2 OVATION 2 study of IMNN-001 in advanced ovarian cancer, showing improved survival and immune response. The trial compared IMNN-001 with chemotherapy against chemotherapy alone. The company is now conducting a Phase 3 trial, OVATION 3, to confirm these results. IMNN-001 is a DNA-based immunotherapy targeting IL-12 delivery to tumor tissue.

$IMNNMed

In an ovarian cancer trial, median survival was 14.7 months longer with added treatment

IMUNON, Inc. (Nasdaq: IMNN) announced new data from its Phase 2 OVATION 2 study, showing that IMNN-001 increased anti-tumoral T-cell activity in ovarian cancer patients. The treatment improved median overall survival by 14.7 months compared to standard care. The findings support the ongoing Phase 3 OVATION 3 trial. The data was presented at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting.